FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
This article was originally published in The Gray Sheet
Executive Summary
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.